Trials / Unknown
UnknownNCT05162196
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Radiotherapy Combined With Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer (CREATE): A Open-label, Single-arm, Phase II Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 57 (estimated)
- Sponsor
- Wuhan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multicenter, open-label study to observe the efficacy and safety of combination with radiotherapy, niraparib and toripalimab in patients With recurrent small cell lung cancer(SCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | SBRT | 24Gy/3F |
| DRUG | Toripalimab | Toripalimab 240mg, ivgtt, d1, q3w. |
| DRUG | Niraparib | 200mg qd |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2024-06-01
- Completion
- 2024-12-01
- First posted
- 2021-12-17
- Last updated
- 2022-05-02
Source: ClinicalTrials.gov record NCT05162196. Inclusion in this directory is not an endorsement.